WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

Eisai announces COFEPRIS approval of Leqembi (lecanemab) for early Alzheimer's disease in Mexico, marking the first treatment to reduce disease progression and cognitive decline by targeting Aβ protofibrils and plaques. Leqembi is also approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, UAE, and Great Britain. The approval is based on Phase 3 Clarity AD trial data, with an estimated 1.3 million Alzheimer's patients in Mexico. The drug is a result of a collaboration between BioArctic and Eisai, with BioArctic responsible for commercialization in the Nordic region pending European approval.

BioArctic's partner Eisai announces COFEPRIS approval of Leqembi for early Alzheimer's disease in Mexico. Leqembi reduces Aβ protofibrils and plaques, slowing cognitive decline. It's also approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, UAE, and Great Britain. Based on Phase 3 Clarity AD trial data, Leqembi met primary and secondary endpoints. Collaboration with BioArctic began in 2005, with Eisai leading clinical development and commercialization.

Deep visceral fat in obese middle-aged people linked to higher Alzheimer's-related amyloid and tau protein levels in the brain, decades before symptoms appear.

Visceral fat in midlife predicts Alzheimer’s risk; obesity linked to higher amyloid levels; MRI and PET scans show visceral fat accounts for 77% of BMI’s effect on amyloid accumulation.

Eisai launched Leqembi in South Korea for mild cognitive impairment due to Alzheimer’s disease or mild AD dementia. Leqembi selectively binds to amyloid-beta aggregates, reducing disease progression and cognitive decline. Developed by BioArctic and Eisai, it is approved in multiple countries and under review in others. BioArctic and Eisai are preparing for joint commercialization in the Nordic region.

Eisai launches Leqembi in South Korea for mild cognitive impairment due to Alzheimer's disease. Leqembi selectively binds to amyloid-beta aggregates, reducing disease progression and cognitive decline. Developed by BioArctic and Eisai, it's the first treatment to show efficacy through this mechanism.

Eisai and Biogen launch LEQEMBI in South Korea, a humanized anti-soluble aggregated amyloid-beta monoclonal antibody for mild cognitive impairment due to Alzheimer's disease or mild AD dementia. LEQEMBI selectively binds to soluble and insoluble Aβ aggregates, reducing both protofibrils and plaques in the brain, and is the first treatment shown to slow cognitive and functional decline.

Nusayba Bagegni, MD, an associate professor of medicine at Washington University School of Medicine in St. Louis, has been awarded a 2024 Early Career Cancer Clinical Investigator Award by the National Cancer Institute. Bagegni, a board-certified medical oncologist, specializes in treating breast cancer and leads clinical trials in early-stage and advanced breast cancer.